Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization-Reference-Cited by-同舟云学术

Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization

Published:2021-10 Issue:10 Volume:14 Page:101165
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Yang George,Yuan Zhigang,Ahmed Kamran,Welsh Eric A.,Fulp William J.,Gonzalez Ricardo J.,Mullinax John E.,Letson Douglas,Bui Marilyn,Harrison Louis B.,Scott Jacob G.,Torres-Roca Javier F.,Naghavi Arash O.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference49 articles.

1. Principles in management of soft tissue sarcoma;Crago;Adv. Surg.,2015

2. NCCN guidelines insights: soft tissue sarcoma, Version 1.2021;von Mehren;J. Natl. Compr. Canc. Netw.,2020

3. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity;Yang;J. Clin. Oncol.,1998

4. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial;O'Sullivan;Lancet,2002

5. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas;Eilber;J. Clin. Oncol.,2001

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of palliative radiation dose on symptom response in metastatic sarcomas;Clinical and Translational Radiation Oncology;2024-09

2. Progress in histology specific treatments in soft tissue sarcoma;Expert Review of Anticancer Therapy;2024-08-05

3. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model;Journal of Medicinal Chemistry;2024-07-16

4. Design of a Fibroblast Activation Protein–Targeted Radiopharmaceutical Therapy with High Tumor–to–Healthy-Tissue Ratios;Journal of Nuclear Medicine;2024-06-13

5. Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma;BMC Cancer;2024-04-09